Source-grounded facts extracted from Benitec Biopharma Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Megan Boston resigned as Director at Benitec Biopharma Inc..
“On May 22, 2026, Megan Boston, the Company’s chief financial officer and secretary and a member of the Board since 2016, notified the Board of her decision to resign solely from the Board and rotated off the Board as part of the Company’s ongoing Board composition and governance review.”
David Friedman was appointed as Director at Benitec Biopharma Inc..
“On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date.”
Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2026 results: net income Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and, EPS $(0.24) per basic and diluted share.
“Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and diluted share”
Benitec Biopharma Inc. reported that prior financial statements should not be relied upon.
“onths ended December 31, 2024, contained in its Quarterly Report on Form 10-Q for the quarter ended December 31, 2024, originally filed with the SEC on February 14, 2025 (collectively, the “Prior Financial Statements”), should no longer be relied upon. The errors and corrective adjustments identified by the Company are non-cash in nature and resulted from the migration, in November 2023, of equity awards data to a new information recording system used to calculate the Company’s share-based compensation expense, which was incorrectly configured resulting in understatements of share-based compensation expense, which in turn led to understatements of additional paid-in capital, accumulated deficit, net loss and loss per share. The impact was immaterial to the Company’s previously issued financial statements prior to the quarter ended December 31, 2024, but the cumulative impact of the incor”
Benitec Biopharma Inc.: Amendment to Certificate of Incorporation to authorize 5,000,000 shares of preferred stock and corresponding change to authorized capital stock (effective 2024-12-09).
“at the Company’s 2024 Annual Meeting of Stockholders held on December 4, 2024, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended, to authorize the issuance of 5,000,000 shares of preferred stock, par value $0.0001, and to make a corresponding change to the number of authorized shares of capital stock.”
Kishan Mehta was appointed as Director at Benitec Biopharma Inc..
“On June 26, 2024, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed Kishan (“Kishen”) Mehta to serve as a director of the Board, effective as of June 26, 2024.”
Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2024 results: revenue $0.
“Total Revenues for the quarter ended March 31, 2024, were $0 compared to $54,000 in licensing revenues collected for the quarter ended March 31, 2023.”
Benitec Biopharma Inc. entered into Voting Commitment Agreement with the Purchasers valued at Company obligated to use reasonable best efforts to obtain stockholder approval for exercise of Pre- (effective 2024-04-22).
“In connection with the Private Placement, the Company intends to enter into a Voting Commitment Agreement with the Purchasers on the Closing Date (the “Voting Commitment Agreement”).”
Benitec Biopharma Inc. entered into Registration Rights Agreement with the Purchasers valued at Company agrees to file a registration statement covering resale of Registrable Securities by 30th ca (effective 2024-04-22).
“In connection with the closing of the Private Placement, on the Closing Date, the Company will enter into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company will agree to register for resale the Shares and the Warrant Shares held by the Purchasers (the “Registrable Securities”).”
Benitec Biopharma Inc. entered into Securities Purchase Agreement with institutional accredited investors valued at aggregate gross proceeds of approximately $40.0 million for 5,749,152 shares at $4.80 per share and (effective 2024-04-17).
“On April 17, 2024, Benitec Biopharma Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”), (i) an aggregate of 5,749,152 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $4.80 per share and (ii) in lieu of shares of Common Stock to certain Purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,584,239 shares of Common Stock (the “Warrant Shares”) at a purchase price of $4.7999 per Pre-Funded Warrant (representing the $4.80 per Share purchase price less the exercise price of $0.0001 per Pre-Funded Warrant Share).”
Benitec Biopharma Inc. reported financial results for fiscal quarter ended December 31, 2023.
“On February 13, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2023.”
Benitec Biopharma Inc. shareholders approved Approval of Amendment to the 2020 Equity and Incentive Compensation Plan at the 2023-12-06 meeting.
“Proposal 4 – Approval of Amendment to the 2020 Equity and Incentive Compensation Plan. The results were as follows: For Against Abstain Broker Non-Vote 1,320,120 56,877 2,778 496,015”
Benitec Biopharma Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-12-06 meeting.
“Proposal 3 – Advisory Vote on Executive Compensation. The results were as follows: For Against Abstain Broker Non-Vote 1,327,852 47,430 4,493 496,015”
Benitec Biopharma Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-12-06 meeting.
“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm. The results were as follows: For Against Abstain 1,782,870 57,064 35,856”
Benitec Biopharma Inc. shareholders approved Election of Directors at the 2023-12-06 meeting.
“Proposal 1 – Election of Directors . The results were as follows: Director Nominee For Withhold Broker Non-Votes Edward Smith 1,324,883 54,892 496,015”
Benitec Biopharma Inc. reported First Fiscal Quarter ended September 30, 2023 results: revenue $0.
“OPMD patient screening and enrollment to begin in Canada. Financial Highlights First Quarter 2024 Financial Results Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022. Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended”
Benitec Biopharma Inc. reported financial results for the fiscal year ended June 30, 2023.
“On September 21, 2023, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal year ended June 30, 2023.”
Benitec Biopharma Inc. entered into Underwriting Agreement with Citizens JMP Securities, LLC valued at approximately $28.3 million (effective 2023-08-08).
“On August 8, 2023, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Citizens JMP Securities, LLC (the “Underwriter”)”
Benitec Biopharma Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“August 9, 2023, the Company received written notice from the Listing Qualifications Department of Nasdaq informing the Company that it has regained compliance with the Bid Price Rule based on the closing price of the Company’s common stock having been at $1.00 per share or greater for 10 consecutive trading days and that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: August 10, 2023 /s/ Jerel”
Benitec Biopharma Inc.: Certificate of Amendment to the Amended and Restated Certificate of Incorporation to effect a 1-for-17 reverse stock split (effective 2023-07-26).
“On July 25, 2023, Benitec Biopharma Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on July 26, 2023 (the “Effective Time”), a 1-for-17 reverse stock split (the “Reverse Stock Split”)”
Benitec Biopharma Inc. reported financial results for Third Fiscal Quarter ended March 31, 2023.
“On May 15, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2023.”
Benitec Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“March 7, 2023, Nasdaq notified the Company in writing that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180 calendar day period, or until September 5, 2023, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq of its intention to cure th”
Benitec Biopharma Inc. reported financial results for Second Fiscal Quarter ended December 31, 2022.
“On February 13, 2023 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2022.”
Benitec Biopharma Inc.: Increased authorized shares of common stock from 40,000,000 to 160,000,000 (effective 2022-12-09).
“the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock of the Company from 40,000,000 to 160,000,000.”
Benitec Biopharma Inc. shareholders approved Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies at the 2022-12-07 meeting.
“Proposal 7 – Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies. The results were as follows: For Against Abstain 15,968,583 2,905,589 119,984”
Benitec Biopharma Inc. shareholders approved Approval of an Amendment to the Company's Certificate of Incorporation to Effect a Reverse Stock Split of the Company's Common Stock at the 2022-12-07 meeting.
“Proposal 6 – Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split of the Company’s Common Stock. The results were as follows: For Against Abstain 17,463,834 1,528,782 1,540”
Benitec Biopharma Inc. shareholders rejected Approval of an Amendment to the Company's Certificate of Incorporation to Authorize the Issuance of Up to 5,000,000 Shares of Preferred Stock at the 2022-12-07 meeting.
“Proposal 5 – Approval of an Amendment to the Company’s Certificate of Incorporation to Authorize the Issuance of Up to 5,000,000 Shares of Preferred Stock. The results were as follows: For Against Abstain Broker Non-Vote 12,501,121 1,316,881 3,746 5,172,408”
Benitec Biopharma Inc. shareholders approved Approval of an Amendment to the Company's Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2022-12-07 meeting.
“Proposal 4 – Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock. The results were as follows: For Against Abstain 15,970,145 2,906,409 117,602”
Benitec Biopharma Inc. shareholders approved Advisory Vote on Executive Compensation at the 2022-12-07 meeting.
“Proposal 3 – Advisory Vote on Executive Compensation. The results were as follows: For Against Abstain Broker Non-Vote 13,411,245 396,016 14,487 5,172,408”
Benitec Biopharma Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2022-12-07 meeting.
“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm. The results were as follows: For Against Abstain 18,739,378 137,128 117,650”
Benitec Biopharma Inc. shareholders approved Election of Directors at the 2022-12-07 meeting.
“Proposal 1 – Election of Directors . The results were as follows: Director Nominee For Withhold Broker Non-Votes Dr. Jerel Banks 13,564,345 257,403 5,172,408 Megan Boston 13,528,333 293,415 5,172,408”
Benitec Biopharma Inc. reported financial results for its fiscal quarter ended September 30, 2022.
“On November 10, 2022 Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.